יחס מהיר: Reneo Pharmaceuticals (RPHM)

Reneo Pharmaceuticals (RPHM) is creating a closed-loop therapy system for rare myopathies, utilizing unique patented solutions for mitochondrial stimulation. The market is currently cautiously assessing the biotech's updated strategic direction, stabilizing confidence in the brand. This price trend reflected below on GURU.Markets shows a coefficient of 58.39, while the company earns from investments awaiting the market launch of drugs for cellular metabolic disorders.

The quick ratio measures a company's ability to meet its short-term obligations using cash and accounts receivable, completely ignoring illiquid inventories. Analyzing the quick ratio allows an investor to identify hidden cash gaps and assess the real quality of capital. The trend of this metric is critical for evaluating solvency. For Reneo Pharmaceuticals (RPHM), this is the primary indicator of whether there is sufficient cash runway to complete clinical trials.